About Wockhardt Limited



Wockhardt Limited is an Indian pharmaceutical and biotechnology company with its head office in Mumbai, Maharashtra, India. Founded by Dr. Habil Khorakiwala in the 1960s, Wockhardt has a presence in the fields of Pharmaceuticals, Biotechnology, Active Pharmaceutical Ingredients (APIs) and Super Speciality Hospitals. The company has full-fledged operations in India, USA, UK, Ireland and France, and a marketing presence in emerging markets like Russia, Brazil, Mexico, Vietnam, Philippines, Nigeria, Kenya, Ghana, Tanzania, Uganda, Nepal, Myanmar, Sri Lanka, Mauritius, Lebanon and Kuwait.


The company’s super specialty hospitals offer treatment and care facilities in cardiology, neurosurgery, orthopedics, critical care, oncology, nephrology, urology, among others.


As of 31st March 2016, the company (as per its website):

  • Reported primary sales revenues USD 673 million (?4,461 crore), out of which:

    • International business accounted for 68% of total sales

    • Domestic business accounted for 32% of total sales

  • Had 14 manufacturing facilities strategically located across India, US and Europe

  • Had 12 contract manufacturing facilities strategically located throughout Europe and Asia

  • Had 3 R&D Centers (India, UK & USA)

    • 822 research professionals including 99 doctorates

    • 15% of total sales in R&D investments

    • Was the only company in the world to have 5 experimental antibiotic drugs with QIDP status granted by US FDA

  • Enjoyed the 4th and 5th position in Pain Management and Vaccines in India

  • Had 7 of its brands among the Top 300 brands in the India Pharma Market (IPM)


Other Highlights


  • The largest Indian generics company in the United Kingdom (Wockhardt UK)

  • The #1 branded generics company in Ireland (Wockhardt's Pinewood)

  • The 4th company in the world to develop recombinant insulin from concept to market stage (Wosulin)

  • The 1st company in the world (after the originator) to develop and market glargine, a long acting insulin analogue (Glaritus)

  • Awarded (4 times in a row) the prestigious Patent Award by the Government of India, for the Maximum Number of Patent Filings & Grants from India

  • Recipient of the prestigious Worldstar Award, the highest recognition in packaging

  • A Business Superbrand for 2 consecutive years

  • Associated with Partners Harvard Medical International, the international arm of Harvard Medical School, USA (Wockhardt Hospitals)


Wockhardt Limited is listed on the National Stock Exchange of India (NSE) and the Bombay Stock Exchange (BSE).


Wockhardt Limited at-a-glance


  • Employees 10,000+
  • Turnover (31 March, 2015) ~USD 673m
  • Major Markets India, USA,
    UK, Ireland,
  • Manufacturing Facilities 14
  • Contract Manufacturing Facilities 12
  • R&D Centers 3
  • Patents Filed 2,579
  • Patents Granted 441
  • ANDAs Filed (2015-16) 17
  • ANDAs Pending Approval 84
  • QUIDPs1 Filed in 2015-16 3







Annual Report 2015-16

Company Website

Company Fact Sheet




Prior to Wockhardt’s formation in 1967 by Dr. Habil Khorakiwala, Worli Chemical Works was acquired by the founder’s father, Mr. Fakhruddin T Khorakiwala, in 1959. The company was subsequently incorporated as Wockhardt Pvt. Ltd. and Wockhardt Ltd. (1999).

The company’s long term outlook continues to look optimistic due to:

  • The growth of the global pharmaceutical industry

  • The company’s sustained focus on R&D, especially complex generics, biotechnology and NCE programs 

  • Expanding reach in regulated markets and sustained efforts to enhance presence in emerging markets like Russia, Brazil, Mexico, Vietnam, Philippines, Nigeria, Kenya, Ghana, Tanzania, Uganda, Nepal, Myanmar, Sri Lanka, Mauritius, Lebanon and Kuwait

  • Increasing number of niche and complex generic products in the pipeline




The company has not shared this information



  • Founder, Chairman & Group CEO: Dr. Habil Khorakiwala

  • Non-Executive Independent Director: Mr. Shekhar Datta

  • Non-Executive Independent Director: Mr. Aman Mehta

  • Non-Executive Independent Director: Mr. DS Brar

  • Non-Executive Independent Director: Dr. Sanjay Baru

  • Non-Executive Independent Director: Mrs. Tasneem Mehta

  • Non-Executive Independent Director: Mr. Baldev Raj Arora

  • Executive Director: Dr. Huzaifa Khorakiwala

  • Managing Director: Dr. Murtaza Khorakiwala





Wockhardt Limited

Wockhardt Towers

Bandra Kurla Complex, Bandra (East)





Website: http://www.wockhardt.com/

Tel: +91 22 2653 4444

Fax: +91 22 2652 3905

+91 22 2652 2929



Tel: +91 022 2653 4444 Ext. 6219 (Board No.)

Tel: +91 022 2659 6219 (Direct)

Fax: +91 022 2653 4242

Email: investorrelations@wockhardt.com


Wockhardt USA LLC

20 Waterview Boulevard, 3rd Floor

Parsippany NJ 07054-1271



Tel: +1 973 2574960

Fax: +1 973 2574961


Morton Grove Pharmaceuticals Inc.

6451 Main Street

Morton Grove, Illinois 60053-2633



Tel: +1 847 9675600

Fax: +1 847 9672211



Wockhardt Bio AG

Grafenauweg 6

6300 Zug



Tel: +41 41 7275220

Fax: +41 41 7275221


Wockhardt UK Limited

Ash Road North

Wrexham Industrial Estate

Wrexham, LL13 9UF Wales

United Kingdom


Tel: +44 1978 661261

Fax: +44 1978 660130


Pinewood Healthcare

Ballymacarbry, Clonmel

Co. Tipperary


Tel: +353 52 6186000

Fax: +353 52 6136311


Laboratoires Negma

Buroplus 3

Za De La Clef St Pierre

1 Bis Avenue Jean D'alembert

Cs 80563

78996 Elancourt Cedex



Tel: (0033) 161 3720 00

Fax: (0033) 161 3720 30


Qualified Infectious Disease Product (QIDP). The QIDP status is granted to drugs that act against pathogens which have a high degree of unmet needs in their treatment. It allows for fast track review of the drug application by the US FDA, and paves way for an early launch.


* Indicates mandatory field.
Please wait while comments are being sent...